書誌事項
- タイトル別名
-
- Bio-nanocapsules for <i>In vivo</i> Pinpoint Drug Delivery
- セイタイナイ ピンポイント トウヨ オ カノウ ニ スル バイオナノカプセル
- Bio-nanocapsules for in vivo pinpoint drug delivery
この論文をさがす
説明
To maximize the beneficial effects and minimize the side effect of drugs, DDS (drug delivery system) has been attracted many researchers in the recent drug development. Especially, the in vivo pinpoint delivery system for drugs is very important and key technology for developing the next generations of anti-cancer drugs and gene therapies. Bio-nanocapsule (BNC) is recombinant yeast-derived hepatitis B virus surface antigen particle, which has been used as a recombinant hepatitis B vaccine for the last 20 years in the world. BNC can incorporate various materials (chemical compounds, proteins, genes, siRNA, etc) by the fusion with liposome, and deliver them to the organs and tissues in vivo specifically by the action of bio-recognition molecules on the BNC's surface. The transfection efficiency is significantly higher than that of liposome, because BNC harbors the complete set of hepatitis B virus infection machinery. Recently, we succeeded in the in vivo retargeting of BNC by displaying either antibody or homing peptide, less than 10 amino acid residues for in vivo targeting. BNC is a hybrid of liposome and virus, and very flexible system for in vivo retargeting. BNC might be very promising carriers in the next generation of DDS.<br>
収録刊行物
-
- 薬学雑誌
-
薬学雑誌 127 (5), 797-805, 2007-05-01
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681103853056
-
- NII論文ID
- 110006273924
-
- NII書誌ID
- AN00284903
-
- ISSN
- 13475231
- 00316903
-
- NDL書誌ID
- 8813073
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可
